MedTrace Logo

Class II Invariant Chain HCV Vaccine Study

NCT03688061 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-05-10

No results posted yet for this study

Summary

The study is aimed at assessing the safety and immunogenicity of HCV prime-boost vaccinations ChAd3-hliNSmut and MVA-hliNSmut, administered intramuscularly in healthy volunteers and DAA treated patients.

Conditions

  • Hepatitis C

Interventions

BIOLOGICAL

ChAd3-hliNSmut

Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV

BIOLOGICAL

MVA-hliNSmut

Modified Vaccinia Ankara (MVA) vectored vaccine against HCV

Sponsors & Collaborators

  • Oxford University Hospitals NHS Trust

    collaborator OTHER

  • ReiThera Srl

    collaborator INDUSTRY

  • European Commission

    collaborator OTHER

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Oxford

    lead OTHER

Principal Investigators

  • Eleanor Barnes, Professor · University of Oxford

  • Lucy Dorrell, Professor · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-04
Primary Completion
2019-08-04
Completion
2022-08-04

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688061 on ClinicalTrials.gov